10-Q: SAB Biotherapeutics Secures $175M, Advances T1D Drug

Sentiment:

Quarterly Report 13 November 2025 5:43 PM

📋All filings for Sab Biotherapeutics, INC

SAB Biotherapeutics reported a significant financial turnaround in Q3 2025, driven by a $175 million capital raise and reclassification of warrants, while advancing its lead T1D candidate, SAB-142, into Phase 2b.

Capital raiseOn July 21, 2025, the company entered into the July 2025 Purchase Agreement for a private placement (Series B Offering).The Series B Offering involved the issuance and sale of 1,000,000 Series B Shares, Release Date Warrants to purchase up to 500,000 shares of Series B Preferred Stock, and Enrollment Date Warrants to purchase up to 1,000,000 shares of Series B Preferred Stock.The aggregate gross proceeds from the Series B Offering were $175 million, with net proceeds of $163.9 million after deducting $11.1 million in offering costs.The net proceeds are intended to fund the Phase 2b SAFEGUARD study of SAB-142 and for general corporate purposes.The company also has a Shelf Registration Statement on Form S-3, declared effective May 17, 2023, allowing it to offer and sell up to $50.0 million in various securities.A Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. allows for the sale of up to $20.0 million in common stock, though the company does not currently plan to issue or sell shares under this agreement.The company explicitly states it will require additional capital to fund operations for long-term plans beyond the next twelve months and may seek future funding through equity or debt financings, or other arrangements.

Better than expectedThe company reported a net income of $45.4 million for Q3 2025 and $30.1 million for the nine months, a significant improvement from net losses in the prior year periods.Cash and cash equivalents increased substantially to $29.4 million, and total assets grew significantly to $183.4 million, primarily due to a successful $175 million capital raise.The accumulated deficit was reduced by over $30 million, indicating improved financial health.The reclassification of $90.7 million in warrant liabilities to equity strengthened the balance sheet.

Summary

The company reported a net income of $45.4 million for the three months ended September 30, 2025, a substantial improvement from a $10.3 million net loss in the prior year period.
For the nine months ended September 30, 2025, net income was $30.1 million, compared to a $22.7 million net loss in the corresponding period of 2024.
Cash and cash equivalents significantly increased to $29.4 million as of September 30, 2025, up from $8.9 million at December 31, 2024.
Total assets surged to $183.4 million from $44.2 million, primarily driven by a $175 million gross proceeds Series B Offering and increased investments.
Stockholders approved the conversion of Series B Preferred Stock into Common Stock on September 26, 2025, leading to the reclassification of associated warrants from liabilities to equity.
Research and development expenses increased by 14.5% to $8.97 million in Q3 2025 and 4.5% to $23.6 million for the nine months, reflecting continued investment in the lead candidate, SAB-142.
No revenue was recognized for the three and nine months ended September 30, 2025, following the termination of prior government grants in 2022.
The accumulated deficit was reduced to $94.0 million as of September 30, 2025, from $124.2 million at December 31, 2024.

Sentiment

Score: 8

Explanation: The company achieved a significant financial turnaround with a large capital raise, substantially improving its liquidity and balance sheet. Positive clinical progress for its lead candidate, SAB-142, with FDA alignment for Phase 2b, indicates strong operational momentum. While operating losses persist and future capital needs are acknowledged, the successful financing and clinical advancement are strong positive indicators.

Positives

Achieved a net income of $45.4 million in Q3 2025 and $30.1 million for the nine months, marking a significant financial turnaround from prior year losses.
Successfully raised $175 million in gross proceeds from the Series B Offering, substantially improving liquidity and capital resources.
Cash and cash equivalents increased by over 230% to $29.4 million, and total investments (short-term and long-term) grew significantly, bolstering the balance sheet.
Received FDA Investigational New Drug (IND) clearance for SAB-142 in May 2024 and announced positive topline data from its Phase 1 clinical trial in January 2025.
Secured "clear, constructive, and actionable guidance" from the FDA during a Type B meeting in May 2025, leading to alignment on the Phase 2b SAFEGUARD study design for SAB-142.
Reduced the accumulated deficit by over $30 million, from $124.2 million to $94.0 million, indicating improved financial health.
Reclassified $90.7 million in warrants from liabilities to stockholders' equity following shareholder approval, further strengthening the balance sheet.

Negatives

No revenue was generated for the three and nine months ended September 30, 2025, due to the termination of prior government grants.
Operating expenses increased, with Research and Development up 14.5% in Q3 and 4.5% for the nine months, indicating a continued high burn rate for development activities.
Net cash used in operating activities increased by $3.2 million to $28.0 million for the nine months ended September 30, 2025.
Diluted earnings per share remained negative at $(0.21) for Q3 2025 and $(0.33) for the nine months, despite positive basic EPS, due to the dilutive impact of in-the-money warrants.
The company anticipates continued losses for the foreseeable future and expects these losses to increase as it develops product candidates and seeks regulatory approvals.

Risks

The company will require additional capital to fund operations and support long-term plans beyond the existing resources, which are sufficient for the next twelve months.
The sale of common stock issuable upon conversion of Series B Preferred Stock and exercise of warrants could represent a significant number of securities in the public market, potentially causing the market price of the company's securities to decline.
Disruptions at the FDA or other government agencies (e.g., due to budget, funding, personnel changes, or shutdowns) could delay product review/approval or impact funding for research and development and clinical trials.
The company currently has no commercially approved products, and there is no assurance that its research and development efforts will be successfully commercialized.
Developing and commercializing a product requires significant time and capital and is subject to regulatory review, approval, and competition from other biotechnology and pharmaceutical companies.
The company operates in an environment of rapid change and is dependent upon the continued services of its employees and obtaining and protecting intellectual property.
The company's estimated probability of dissolution, should its intellectual property fail to yield positive results in forthcoming clinical trials, was 38.5% as of September 30, 2025.

Future Outlook

The company anticipates continued losses for the foreseeable future and expects these losses to increase as it advances product candidates through development and seeks regulatory approvals. Research and development expenses are projected to increase as SAB-142 progresses through Phase 2 clinical trials and towards potential commercialization. General and administrative expenses are also expected to rise with workforce expansion and increased operational complexity. While existing resources are expected to cover operating cash needs for the next twelve months, additional capital will be required for long-term plans, potentially through equity or debt financings, or collaborative arrangements.

Management Comments

"We anticipate that we will continue to generate losses for the foreseeable future and expects the losses to increase as we continue the development of, or seeks regulatory approvals for product candidates, and begins commercialization of products."
"Based on our current level of operating expenses, existing resources will be sufficient to cover operating cash needs through the twelve months following the date of this report."
"In the future, we may seek additional funding through a combination of equity or debt financings, or other third-party financing, collaborative or other funding arrangements."
"We expect research and development expenses to increase in future years as we advance our lead therapeutic candidate through Phase 2 clinical trials and invest in the necessary foundation to support potential commercialization."
"We anticipate that general and administrative expenses will rise as we expand our workforce and invest in the advancement of our lead therapeutic candidate in preparation for potential commercialization."

Industry Context

SAB Biotherapeutics operates in the highly competitive and capital-intensive biopharmaceutical industry, specifically targeting autoimmune disorders like Type 1 Diabetes (T1D) with its lead candidate, SAB-142. The company's proprietary platform for generating human polyclonal immunotherapeutic antibodies (hIgG) without human donors offers a differentiated approach, potentially providing a 'best-in-class' or 'first-in-class' therapy. The successful capital raise and advancement of SAB-142 into Phase 2b are critical milestones in an industry where clinical trial success and regulatory approval are key value drivers. The focus on T1D, a significant unmet medical need, positions the company in a high-potential market, but also one with substantial development risks and competition from other biotechnology and pharmaceutical companies.

Comparison to Industry Standards

The company's proprietary platform for generating multi-specific, high-potency hIgGs without human donors or convalescent plasma is presented as a unique differentiator, offering a significant barrier to competitive polyclonal approaches due to no biosimilar pathway.
SAB-142, a human anti-thymocyte globulin (hATG), aims to provide superior efficacy and safety in delaying T1D progression, building on the clinically validated mechanism of action of rabbit anti-thymocyte globulin (rATG) which has shown ability to slow disease progression in T1D.
The company highlights data from over 700 human subjects treated with antibodies from its platform, supporting an expectation of zero serum sickness rate and zero incidence of neutralizing anti-drug antibodies (ADA) in upcoming SAB-142 trials, which would be a favorable safety profile compared to some existing antibody therapies.
The progression of SAB-142 into a Phase 2b clinical trial (SAFEGUARD study) after positive Phase 1 data and FDA alignment is a standard advancement path for biopharmaceutical companies, indicating adherence to regulatory development timelines.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Equity Incentive Plan Amendment	Stockholders approved an amendment to the 2021 Equity Incentive Plan at the 2024 Annual Meeting, increasing shares available for grant by 3,900,000 and the annual increase from 2% to 5%.	June 2024	Expands the pool of shares available for employee and director compensation, potentially aiding talent retention and alignment with company performance.
Equity Incentive Plan Amendment	Stockholders approved a further amendment to the 2021 Equity Incentive Plan at the 2025 Special Meeting, increasing shares available for grant by 24,180,000 and the maximum annual increase from 10,000,000 shares to 73,750,000 shares.	September 26, 2025	Significantly expands the potential for equity-based compensation, which could be dilutive but also serves as a strong incentive for management and employees.
Shareholder Approval for Conversion	Stockholders approved the issuance of all shares of Common Stock issuable upon conversion of the Series B Preferred Stock at the 2025 Special Meeting, leading to the reclassification of Series B Preferred Stock and associated warrants from liabilities to equity.	September 26, 2025	Strengthens the balance sheet by moving significant warrant liabilities to equity and facilitates the conversion of preferred stock, potentially increasing the common share count and impacting dilution.

Legal Proceedings

The company is not currently a party to any material litigation, nor is it aware of any pending or threatened litigation that would materially affect its business, operating results, financial condition, or cash flows.

Related Party Transactions

No related party transactions with beneficial owners of 5% or more of voting securities, immediate family members, or associated entities were reported for the three and nine months ended September 30, 2025 and 2024.

Stakeholder Impact

Shareholders: Significant increase in total stockholders' equity and a reduction in accumulated deficit are positive. However, potential dilution from future capital raises and the conversion of Series B Preferred Stock and warrants could impact existing share value. The registration of shares for resale could also put downward pressure on the stock price.
Employees: Continued investment in R&D and anticipated workforce expansion suggest job stability and growth opportunities. Stock-based compensation plans are in place.
Customers (future): Advancement of SAB-142 into Phase 2b trials brings the company closer to potentially offering a new treatment for Type 1 Diabetes.
Creditors: Improved liquidity and a stronger balance sheet following the capital raise enhance the company's ability to meet its financial obligations.

Next Steps

Advance SAB-142 into a Phase 2b clinical trial called the SAFEGUARD study, which is expected to start in December 2025.
Conduct discovery research to enhance the proprietary platform and work on other autoimmune indications.
Expand workforce and invest in the advancement of the lead therapeutic candidate in preparation for potential commercialization.
Potentially seek additional funding through equity or debt financings, or other third-party arrangements to support long-term plans.
Continue to incur higher costs related to accounting, audit, legal, regulatory compliance, director and officer insurance, and investor relations as operations grow in complexity and progress toward commercialization.

Key Dates

Date	Description
June 2014	Initial start date of operating lease for lab space from Sanford Health.
December 2018	Entered into a finance lease with Dakota Ag Properties for a new animal facility.
June 2019	Initial end date of operating lease for lab space from Sanford Health, subsequently extended.
November 2020	Entered into a lease for office, laboratory, and warehouse space.
October 22, 2021	Closing Date of the business combination with Big Cypress Acquisition Corp., when BCYP changed its name to SAB Biotherapeutics, Inc. Also, the expiration date for Public and Private Placement Warrants is the fifth anniversary of this date.
December 2022	Entered into a securities purchase agreement for PIPE Warrants and PIPE Placement Agent Warrants.
March 21, 2023	Entered into a settlement agreement with Ladenburg Thalmann & Co. Inc. (effective March 23, 2023).
May 3, 2023	Filed a Shelf Registration Statement on Form S-3.
May 17, 2023	Shelf Registration Statement declared effective by the SEC.
June 2023	Formed SAB BIO PTY LTD subsidiary in Australia.
June 30, 2023	Issued 191,689 shares of common stock to satisfy a portion of obligations under the 2023 Ladenburg Agreement.
September 29, 2023	Entered into a securities purchase agreement for the September 2023 Offering of Series A Preferred Stock and Preferred Warrants.
November 2023	Renewed lease for office, laboratory, and warehouse space.
November 21, 2023	Issued Preferred PIPE Placement Agent Warrants to Chardan Capital Markets LLC.
December 31, 2023	Deadline for final $1.1 million payment to Ladenburg under the 2023 Ladenburg Agreement.
January 26, 2024	Entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co.
April 2024	Entered into a lease for new principal executive office space in Miami Beach, Florida.
May 2024	Received Investigational New Drug (IND) clearance from the FDA for SAB-142.
June 2024	Held the 2024 Annual Meeting of Stockholders, approving an amendment to the 2021 Equity Incentive Plan.
September 22, 2024	Final installment payment made on prior insurance financing agreement with First Insurance Funding.
December 31, 2024	All obligations under US Department of Defense grants satisfied.
January 1, 2025	42,846 Preferred Tranche B Warrants expired unexercised.
January 2025	Renewed operating lease for lab space from Sanford Health for a five-year term.
January 2025	Announced positive topline data from Phase 1 clinical trial of SAB-142.
May 29, 2025	Held a constructive Type B meeting with the FDA regarding SAB-142's Phase 2b SAFEGUARD clinical trial design.
June 22, 2025	Final payment made on current insurance financing agreement with AFCO Direct.
July 21, 2025	Entered into the July 2025 Purchase Agreement for the Series B Offering.
July 22, 2025	Closing of the Series B Offering.
September 26, 2025	Held the 2025 Special Meeting of stockholders, approving the issuance of common stock upon conversion of Series B Preferred Stock and an amendment to the 2021 Equity Incentive Plan.
September 30, 2025	End of the reporting period for this 10-Q filing. Also, the registration statement for resale of Series B conversion shares was declared effective.
December 2025	Expected start date for the Phase 2b SAFEGUARD study for SAB-142.
October 22, 2026	Expiration date for Public Warrants and Private Placement Warrants.
October 2, 2028	Expiration date for Preferred PIPE Placement Agent Warrants.
December 31, 2029	End of renewed operating lease term for lab space from Sanford Health. Also, end of initial term for Miami Beach office lease.

Recommendation

hold

The company has significantly strengthened its financial position through a substantial capital raise and improved its balance sheet by reclassifying warrants to equity, leading to a positive net income for the period. Clinical progress with SAB-142, including FDA alignment for Phase 2b, is a positive operational development. However, the company remains in a development phase with no current revenue from product sales and anticipates continued losses. The need for future capital raises and potential dilution from the conversion of Series B shares and warrants present ongoing risks. Given the early stage of clinical development for its lead candidate and the inherent uncertainties in biopharmaceutical commercialization, a 'hold' recommendation is appropriate. Investors should monitor the progress of the SAFEGUARD study and future financing activities.

Keywords

SAB Biotherapeutics, SABS, 10-Q, Quarterly Report, Biopharmaceutical, Type 1 Diabetes, T1D, SAB-142, hATG, Clinical Trial, Phase 2b SAFEGUARD, FDA, Capital Raise, Series B Offering, Warrants, Equity Financing, Research and Development, Financial Results, Immunotherapy, Autoimmune Disorders, SEC Filing

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.